- Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies
- First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments
- FIRST LIGHT ACQUISITION GROUP, INC. Further Adjourns Special Meeting of Stockholders to August 28, 2023 at 10:30 am ET
- FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to August 24, 2023 at 10:30 am ET
- Flag Stockholders: Reminder to Vote for Proposed Business Combination
- First Light Acquisition Group, Inc. Announces Effectiveness of Registration Statement and Sets August 22, 2023 as Date of Stockholder Meeting for the Calidi Business Combination
More ▼
Key statistics
On Wednesday, Calidi Biotherapeutics Inc (CLDI:ASQ) closed at 0.1939, 35.12% above the 52 week low of 0.1435 set on Apr 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.2025 |
---|---|
High | 0.21 |
Low | 0.19 |
Bid | 0.1939 |
Offer | 0.202 |
Previous close | 0.2024 |
Average volume | 548.20k |
---|---|
Shares outstanding | 50.92m |
Free float | 30.92m |
P/E (TTM) | -- |
Market cap | 9.87m USD |
EPS (TTM) | -0.6765 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 22:00 BST.
More ▼